SMITHKLINE PAXIL HAS SWIFTEST RATE OF SALES, Rx GROWTH AMONG SSRIs, COMPANY TELLS ANALYSTS; HAVRIX INTERNET AD CAMPAIGN FOCUS EXPANDING TO GAY MEN
Executive Summary
SmithKline Beecham's serotonin reuptake inhibitor Paxil is third in its class but growing most rapidly in the U.S. with a 39% jump in 1996, the company reported at a meeting with analysts in New York City on Feb. 18. Pfizer's Zoloft sales gained 27% while Lilly's Prozac grew 20%.